Drugs / Boswellia carterii Extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07576634 | Jan → Dec 2025 | irritable bowel syndrome | Mansoura University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boswellia carterii Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07576634 ↗ |
| Action | Inhibit | “inhibit leukotriene synthesis through suppression of 5-lipoxygenase activity” NCT07576634 ↗ |
| Route | Oral | “was administered orally twice daily with meals” NCT07576634 ↗ |